Trials of a new coronavirus (COVID-19) treatment found hospital patients who took the drug had a 79% lower risk of developing severe disease.
Pharmaceutical company Synairgen has developed the drug, currently called SNG001. It is a special formulation of the anti-viral protein interferon beta. Patients inhale the drug directly into the lungs.
Previous studies involving asthmatic patients have shown they generally tolerate the drug well. It enhances the lungs’ anti-viral defences and improves lung function during cold or flu infection.
More than twice as likely to recover
In the current trial, each patient received either the drug or a placebo. But neither the researchers nor the 101 patients knew whether they were receiving SNG001. Early results suggest patients were more than twice as likely to recover from Covid-19 as those who received a placebo.
It found that the odds of developing severe disease – needing ventilation or resulting in death – during the treatment period of up to 16 days were reduced by 79% for patients receiving the drug, compared with patients who received the placebo.
Results also indicate that, over the treatment period, breathlessness reduced significantly in patients who received SNG001.
Three people (6%) who took the placebo died. But there were no deaths among those who received the drug, Synairgen said.
Study participants with more severe disease at time of admission were more likely to be discharged with SNG001 treatment. But researchers say the difference was not statistically significant.
Professor of respiratory medicine at the University of Southampton Tom Wilkinson is chief investigator on the trial. He is “delighted with the positive data produced from this trial”. He added:
The results confirm our belief that interferon beta, a widely known drug that, by injection, has been approved for use in a number of other indications, has huge potential as an inhaled drug to be able to restore the lungs’ immune response, enhancing protection, accelerating recovery and countering the impact of Sars-CoV-2 virus.
Professor Stephen Holgate, Medical Research Council clinical professor of immunopharmacology at the University of Southampton and co-founder of Synairgen, said the treatment:
restores the lungs’ ability to neutralise the virus, or any mutation of the virus or co-infection with another respiratory virus such as influenza or RSV, as could be encountered in the winter if there is a resurgence of Covid-19.”
We need your help to keep speaking the truth
Every story that you have come to us with; each injustice you have asked us to investigate; every campaign we have fought; each of your unheard voices we amplified; we do this for you. We are making a difference on your behalf.
Our fight is your fight. You’ve supported our collective struggle every time you gave us a like; and every time you shared our work across social media. Now we need you to support us with a monthly donation.
We have published nearly 2,000 articles and over 50 films in 2021. And we want to do this and more in 2022 but we don’t have enough money to go on at this pace. So, if you value our work and want us to continue then please join us and be part of The Canary family.
In return, you get:
* Advert free reading experience
* Quarterly group video call with the Editor-in-Chief
* Behind the scenes monthly e-newsletter
* 20% discount in our shop
Almost all of our spending goes to the people who make The Canary’s content. So your contribution directly supports our writers and enables us to continue to do what we do: speaking truth, powered by you. We have weathered many attempts to shut us down and silence our vital opposition to an increasingly fascist government and right-wing mainstream media.
With your help we can continue:
* Holding political and state power to account
* Advocating for the people the system marginalises
* Being a media outlet that upholds the highest standards
* Campaigning on the issues others won’t
* Putting your lives central to everything we do
We are a drop of truth in an ocean of deceit. But we can’t do this without your support. So please, can you help us continue the fight?